Syeda Asiya Butool¹*, Syed Murtuza Kirmani², Shyam Agrawal¹ Sandhya Gananjay Salve¹ and Nitin Kararia³

¹Department of Conservative Dentistry and Endodontics. MDS Nims University Jaipur, Rajasthan, India
²Department of Anesthesia DNB, Yashoda Hospital, India
³Department of Conservative Dentistry and Endodontics, Nims University Jaipur, Rajasthan, India

*Corresponding Author: Syeda Asiya Butool, Department of Conservative Dentistry and Endodontics, NIMS University, Jaipur, India.

Received: June 15, 2022; Published: August 16, 2022

Abstract

Mucormycosis is a fungus that is caused by mucormycetes, a type of mould with environmental contact with its spores. The entry of fungus into the body is through the skin which is injured or cut., it can develop on the skin. It also erodes face structures and travels across the respiratory tract. It is angioinvasive caused by the fungus Mucorales. It is most frequently encountered in immunocompromised patients. Following covid 19 second wave, there is a rapid increase in mucormycosis incidence in post-covid patients in India. If not treated early on, this disease appears to be fatal.

This review article seeks to provide a quick overview of the etiology, pathogenesis, risk factors, dos and don'ts, as well as recent breakthroughs in Mucormycosis diagnostic and therapeutic procedures.

Keywords: Mucormycosis; Covid 19; Diabetes

References

1. Fürbringer P. “Beobachtungenüber Lungenmycosebeim Menschen”. Virchows Arch 66 (1876): 330-365.
2. Chakrabarti A., et al. “The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus”. Medical Mycology 44 (2006): 335-342.
3. Slavin M., et al. “Invasive infections due to filamentous fungi other than Aspergillus: Epidemiology and determinants of mortality”. Clinical Microbiology and Infection 21 (2015): 490.e1-490.e10.
4. Skied A., et al. “Epidemiology and diagnosis of mucormycosis: An update”. Journal of Fungi (Basel) 6 (2020): 265.
5. Petrikkos G., et al. “Epidemiology and Clinical Manifestations of Mucormycosis”. Clinical Infectious Diseases 54 (2012): S23-S34.
6. Lanternier F., et al. The French Mycosis Study Group. “A Global Analysis of Mucormycosis in France: The Retro Zygo Study (2005-2007)”. Clinical Infectious Diseases 54 (2012): S35-S43.
7. Skiada A., et al. “Zygomycosis in Europe: Analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007”. Clinical Microbiology and Infection 17 (2011): 1859-1867.
8. Patel A., et al. “A multicenter observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India”. Clinical Microbiology and Infection 26 (2020): 944.
9. Jeong W., et al. “The epidemiology and clinical manifestations of mucormycosis: A systematic review and meta-analysis of case reports”. Clinical Microbiology and Infection 25 (2019): 26-34.
10. Santosh G Honavar. “Code Mucor: Guidelines for the Diagnosis, Staging and Management of Rhino- Orbito-Cerebral Mucormycosis in the Setting of COVID-19”. Indian Journal of Ophthalmology6 (2021): 1361-1365.
11. https://www.indiatvnews.com/fyi/mucormycosis-epidemic-icmr-releases-guidelines-dos-and-donts-for- black-fungus-infection-symptoms-706050

Citation

Citation: Syeda Asiya Butool., et al. “Mucormycosis during Covid 19: A Review Article".Acta Scientific Medical Sciences 6.9 (2022): 58-62.

Copyright

Copyright: © 2022 Syeda Asiya Butool., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.